.Pharmacolibrary.Drugs.ATC.C.C07AB14

Information

Landiolol is an ultrashort-acting, highly selective beta-1 adrenergic receptor blocker. It is used mainly for rapid heart rate control in atrial fibrillation or atrial flutter, and for perioperative or ICU tachyarrhythmias. Landiolol is approved and in clinical use in countries such as Japan and several European nations.

Pharmacokinetics

Pharmacokinetics in healthy adult volunteers receiving intravenous infusion.

References

1. Kunisawa, T, et al., & Iwasaki, H (2015). Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients. Journal of anesthesia 29(2) 198–205. DOI:10.1007/s00540-014-1908-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25186494

2. Krumpl, G, et al., & Husch, B (2018). Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites. Journal of cardiovascular pharmacology 71(3) 137–146. DOI:10.1097/FJC.0000000000000554 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29112591

3. Michel-Behnke, I, et al., & Krumpl, G (2025). Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED). Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 27(2) –. DOI:10.1093/europace/euaf025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39947241

Revisions

• 06/2025 initial generated model